Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

O
O’Brien, Susan

UC Irvine, Chao Family Comprehensive Cancer Center
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Susan O’Brien
Favorite
O’Quinn, Rupal

Perelman School of Medicine, University of Pennsylvania
1220 - Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials (RCTs)
Rupal O’Quinn
Favorite
O'brien, Daniel

Mayo Clinic
2006 - Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Daniel O'brien
Favorite
O'Brien, Susan M.

Chao Family Comprehensive Cancer Center, University of California, Irvine
2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Susan M. O'Brien
Favorite
Obrtlíková, Petra

First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Petra Obrtlíková
Favorite
Oellerich, Thomas

Department of Medicine II, Hematology/Oncology, Goethe University Frankfurt
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Thomas Oellerich
Favorite
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Thomas Oellerich
Favorite
Oexle, Horst

Internal Medicine, Academic Teaching Hospital Hall in Triol, Hall in Tirol; present address: Reha Zentrum Münster
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Horst Oexle
Favorite
Oggianu, Valeria

Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS G. Brotzu
1224 - Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.
Valeria Oggianu
Favorite
Ohl, Sibylle

German Cancer Research Center
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Sibylle Ohl
Favorite
Ohshima, Koichi

Kurume University
1126 - Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.
Koichi Ohshima
Favorite
Oliveira, Joana M.

Elli Lily and Company
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Joana M. Oliveira
Favorite
Oliver, Carolina

Hematology Department, CASMU
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Carolina Oliver
Favorite
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Carolina Oliver
Favorite
Olivieri, Jacopo

Clinica Ematologia di Udine
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Jacopo Olivieri
Favorite
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Jacopo Olivieri
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Jacopo Olivieri
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Jacopo Olivieri
Favorite
Olivieri, Stefano
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Stefano Olivieri
Favorite
Oluwole, Olalekan

Vanderbilt University Medical Center
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Olalekan Oluwole
Favorite
Omer, Zulfa

College of Medicine, University of Cincinnati
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Zulfa Omer
Favorite
Ondrisova, Laura

CEITEC MU, Brno, Czech Rep.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Laura Ondrisova
Favorite
Opat, Stephen

Monash Health and Clinical Haematology Unit, Monash University, Clayton
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Stephen Opat
Favorite
Oppelt, Jan

CEITEC MU
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Jan Oppelt
Favorite
Oppezzo, Pablo

Institut Pasteur de Montevideo
1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Pablo Oppezzo
Favorite
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Pablo Oppezzo
Favorite
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Pablo Oppezzo
Favorite
1054 - The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Pablo Oppezzo
Favorite
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Pablo Oppezzo
Favorite
Ortega, Claudia

Institut Pasteur de Montevideo
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Claudia Ortega
Favorite
Osorio, Santiago

Hospital Universitario Gregorio Marañón
1118 - Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Santiago Osorio
Favorite
Othus, Megan

SWOG Statistical Center
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Megan Othus
Favorite
Otto, Oliver
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Oliver Otto
Favorite
Ou, San-San

Bristol Myers Squibb
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
San-San Ou
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
San-San Ou
Favorite
Owen, Carolyn

University of Calgary
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Carolyn Owen
Favorite
Owens, Colette

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Colette Owens
Favorite